Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data OPKO HEALTH, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1,222
1,068
990
902
1,435
1,775
1,004
863
713
607
Cost of revenue
564
61.2
716
545
495
401
Gross profit
658
1,006
288
318
219
206
Research and development
114
126
126
118
75.3
76.9
73.9
89.6
105
124
Selling, general and administrative
407
415
358
343
356
469
373
301
304
223
Operating expenses
1,214
1,242
1,161
1,176
1,378
1,756
1,230
1,021
Operating income
-96.6
-276
-171
-274
57.7
18.8
-226
-157
-152
-117
Interest expense
18.9
12.1
13.5
47.5
0
Interest income
0.03
1.98
3.98
8.43
14.8
Other non-operating income
-0.27
4.52
-6.07
-30.9
-9.03
-32.8
-165
-27.3
142
-124
Pre-tax income
-96.8
-272
-177
-305
48.7
-14
-392
-184
-10.4
-241
Income tax
-56.1
18.9
-38.7
7.06
17.6
15.5
-63.5
4.44
42.8
-15.7
Net income to minority interests
0
0
Net income
-48.4
-305
-153
-315
30.6
-30.1
-328
-189
-53.2
-226
EBITDA
0.03
-174
-73.9
-180
143
97.5
-118
-51.7
-53.9
-25.8
EPS, basic
-0.09
-0.55
-0.27
-0.53
0.05
-0.05
-0.46
-0.25
-0.08
-0.30
EPS, diluted
-0.10
-0.55
-0.27
-0.53
0.05
-0.05
-0.46
-0.25
-0.08
-0.30
Shares, basic (weighted)
551
559
563
595
641
648
719
752
694
751
Shares, diluted (weighted)
556
559
563
595
641
648
719
752
694
751
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
169
91.5
96.5
85.5
72.2
135
153
95.9
427
364
Receivables
220
166
144
135
286
260
127
123
118
90.3
Inventory
47.2
49.3
42.3
53.4
132
86.5
74.1
65.7
56.8
65.8
Other current assets
7.51
9.24
3.85
15.8
5.31
6.2
6.25
7.67
10.7
8.17
Total current assets
484
349
318
324
523
823
395
309
662
582
Property, plant and equipment
123
147
145
127
141
79.7
82.9
75.4
70.1
73.9
Lease right-of-use assets
39.4
37.7
44.2
38.7
68.1
54
46.9
Goodwill
705
717
700
672
681
521
596
598
529
484
Intangible assets
764
684
614
529
475
322
824
740
617
516
Long-term investments
41.1
40.6
31.2
20.7
15.7
10.7
28.1
16.1
54.6
14.2
Other non-current assets
5.76
5.62
7.22
6.89
10.1
9.53
8.68
9.08
18.5
19.5
Total assets
2,767
2,590
2,451
2,309
2,473
2,400
2,167
2,012
2,200
1,932
Accounts payable
53.4
74.3
47.4
62.5
101
82
67
69.7
47.1
41.1
Accrued liabilities
198
226
204
165
241
193
98.3
90.1
118
84.4
Deferred revenue
73.4
56.9
63.5
19.2
15.8
0.26
0
0.01
0.01
Short-term debt
12
11.9
5.85
1.72
1.99
437
1.74
Total current liabilities
263
312
288
249
375
330
213
200
193
147
Long-term debt
0.72
1.57
4.65
3.91
3.84
9.29
7.73
3
2.26
Lease liabilities
27.7
29.8
33.1
28
54.1
48.8
36.8
Other non-current liabilities
202
256
199
87.8
37.1
15.1
27.4
27.2
32.8
22.8
Total liabilities
675
746
660
695
802
715
606
622
835
664
Total debt
12.7
13.5
10.5
270
251
205
256
0.05
437
344
Paid-in capital
2,845
2,889
3,004
3,143
3,153
3,222
3,422
3,433
3,481
3,575
Retained earnings
-730
-1,049
-1,197
-1,511
-1,482
-1,512
-1,823
-2,012
-2,065
-2,291
Treasury stock
-1.91
-1.79
-1.79
-1.79
-1.79
-1.79
-1.79
-1.79
-1.79
-3.18
Other comprehensive income
-27
-0.53
-20.1
-22.1
-4.23
-30.5
-43.3
-38
-56.1
-21
Shareholders' equity
2,046
1,844
1,791
1,615
1,672
1,685
1,562
1,389
1,365
1,268
Total equity
2,046
1,844
1,791
1,615
1,672
1,685
1,562
1,389
1,365
1,268
Total liabilities and equity
2,767
2,590
2,451
2,309
2,473
2,400
2,167
2,012
2,200
1,932
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-48.4
-305
-153
-315
30.6
-30.1
-328
-189
-53.2
-226
Depreciation and amortization
96.6
102
97.3
93.8
85.4
78.7
109
105
98.2
91.6
Stock-based compensation
42.7
28.3
21.8
13.4
8.95
13.6
18.5
11.4
11
10.7
Deferred income tax
-61.5
16.1
-35.1
4.32
15.6
10.2
-74.4
0.15
14.7
-15
Change in receivables
-25.6
58
20.4
7.38
-150
5.23
129
3.41
-0.22
30.2
Change in inventory
-6.61
-3.54
4.59
-12.1
-77.6
30.7
13.7
15.2
4.22
-4.12
Change in payables
-19.8
20.2
-26.1
15.6
37.2
-10.8
-9.39
2.83
-20.7
-14.2
Cash from operations
32
-92.1
-109
-173
39.5
38.3
-95.2
-28.2
-183
-179
Capital expenditures
-18.5
-46.5
-27.9
-12.7
-33.7
-32.2
-24.6
-16.3
-25
-12.3
Acquisitions
15.9
0
0
0
0
-4
-1.76
0
0
Purchases of investments
-14.4
-9.63
-1
-1.2
0
-2
0
-5
0
Sales and maturities of investments
0
2.21
1.52
0
15.1
8.08
115
0.36
167
52.2
Cash from investing
-20.7
-46.7
-26.1
-13.3
-18.3
35.9
91
-18.2
352
230
Debt issued
0
0
250
0
Debt repaid
0
0
-28.8
0
0
0
-3
-146
Stock issued
0
0
92.5
76.1
0
0
Share buybacks
0
0
-90.2
-47
Cash from financing
-35.2
61
141
175
-35.1
-10.4
23
-11.3
184
-118
Exchange rate effect
-1.01
0.47
-0.68
-0.48
0.69
-1.44
-0.34
Net change in cash
-24.9
-77.2
4.97
-11
-13.2
62.5
18.5
-57.3
350
-62.9
Free cash flow
13.5
-139
-137
-185
5.79
6.18
-120
-44.5
-208
-191
Interest paid
2.89
1.31
2.08
11.9
10.9
8.52
7.42
8.14
20.9
37.9
Income taxes paid
-27.1
5.42
-1.41
2.67
-0.9
5.97
8.04
3.71
10
24.5
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.64 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
40.8%
Gross profit / revenue.
Operating margin
-8.2%
Operating income / revenue.
EBITDA margin
7.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-13.6%
Pre-tax income / revenue.
Net margin
-12.4%
Net income / revenue.
FCF margin
-22.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-21.0%
Cash from operations / revenue.
Return on equity (ROE)
-6.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-4.0%
Net income / average total assets.
Return on invested capital (ROIC)
-3.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
21.3%
Research and development expense / revenue.
SG&A / revenue
35.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
1.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
1.8%
Capital expenditures / revenue.
D&A / revenue
15.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-14.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-15.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-15.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-5.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-10.6%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-7.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-6.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-5.4%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-12.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-3.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-4.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
8.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
1.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
3.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.35x
Current assets / current liabilities.
Quick ratio
2.56x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.01x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.29x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
19.1%
Total debt / total assets.
Liabilities / assets
35.3%
Total liabilities / total assets.
Net debt
$48.3M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA
1.16x
Net debt / EBITDA (twelve months), when EBITDA is positive.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.09
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.78
Revenue / diluted weighted shares.
FCF per share
-$0.18
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.16
Cash from operations / diluted weighted shares.
Book value per share
$1.57
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
2.08x
Market cap / revenue.
P/B
1.03x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
5.44x
Market cap / tangible book value, when positive.
EV/Sales
2.16x
Enterprise value / revenue.
EV/EBITDA
30.7x
Enterprise value / EBITDA, when both are positive.
FCF yield
-10.9%
Free cash flow / market cap.
Earnings yield
-6.0%
Net income / market cap (the inverse of P/E).
Shareholder yield
3.8%
(Dividends paid + share buybacks) / market cap.
What was OPKO HEALTH, INC.'s revenue in fiscal 2025?
OPKO HEALTH, INC. reported revenue of $606.9M for fiscal 2025, 14.9% lower than the year before.
Was OPKO HEALTH, INC. profitable in fiscal 2025?
No. It reported a net loss of $225.7M.
How much free cash flow did OPKO HEALTH, INC. generate in fiscal 2025?
Cash from operations of $178.5M minus capital expenditures of $12.3M left free cash flow of -$190.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.